Cohizon Life Sciences Company Profile

Background

Cohizon Life Sciences, formerly known as Sajjan India Ltd., is a leading contract development and manufacturing organization (CDMO) specializing in large-scale production of active ingredients and specialty chemicals. With over 30 years of experience, the company serves regulated markets including the US, Europe, and Japan. In May 2022, Sajjan India Ltd. was acquired by Sona Company Pte. Ltd., an affiliate of CVC, leading to its rebranding as Cohizon Life Sciences. The company's mission is to build sustainable value for customers through customized chemistry-based solutions, aiming to be the partner of choice by providing responsive, reliable, and competitive offerings.

Key Strategic Focus

Cohizon Life Sciences focuses on:

Agrochemicals: Custom manufacturing of active ingredients and advanced intermediates, including fungicides, insecticides, nematicides, and herbicides.

Pharmaceuticals: Production of non-GMP starting materials, intermediates, and building blocks for APIs.

Specialty Chemicals: Manufacturing chemicals for applications in electronics, dyes, pigments, aerospace, and plastic additives.

The company emphasizes innovation, sustainability, and customer-centric solutions, leveraging its advanced manufacturing infrastructure and research capabilities.

Financials and Funding

In May 2022, Cohizon Life Sciences underwent a significant financial transformation when Sona Company Pte. Ltd., an affiliate of CVC, acquired Sajjan India Ltd., leading to its rebranding as Cohizon Life Sciences. This acquisition marked a renewed dedication to customer centricity, innovation, and sustainable practices.

Pipeline Development

Cohizon Life Sciences is actively expanding its capabilities and capacities, particularly in the pharmaceutical sector. The company is investing in new facilities and technologies to meet the growing demand for high-quality intermediates and APIs. Specific product development timelines and clinical trial stages are proprietary and not publicly disclosed.

Technological Platform and Innovation

The company's state-of-the-art Research & Technology (R&T) Centre in Navi Mumbai, established in 2023, spans 54,000 square feet and includes advanced synthesis labs, analytical labs, flow chemistry labs, kilo labs, and dedicated scale-up labs. This infrastructure supports the development of tailored, innovative solutions for clients.

Leadership Team

Rajesh Kumar Srivastava: Managing Director & CEO

Anurag Surana: Chairman and Non-Executive Director

Devendra Kumar Ray: Executive Whole-time Director

Navin Nathani: Chief Information Officer (appointed February 2025)

Nathani brings over 21 years of experience in IT strategy and digital transformation, having previously served as General Manager and Head of IT at Hindalco Industries Limited.

Leadership Changes

In February 2025, Navin Nathani joined Cohizon Life Sciences as Chief Information Officer, bringing extensive experience in IT strategy and digital transformation.

Competitor Profile

Market Insights and Dynamics

The global chemical manufacturing industry is highly competitive, with significant players operating across various segments. The market is characterized by rapid technological advancements, stringent regulatory requirements, and a growing emphasis on sustainable practices.

Competitor Analysis

Cohizon Life Sciences faces competition from major chemical manufacturers such as BASF (Germany), Air Liquide (France), and AkzoNobel (Netherlands). These companies have established global presences and offer a wide range of chemical products and services.

Strategic Collaborations and Partnerships

Cohizon Life Sciences has built long-standing relationships with global innovator chemical leaders, focusing on creating sustainable value through responsible actions. Specific details of these collaborations are proprietary.

Operational Insights

The company's manufacturing infrastructure includes two state-of-the-art production sites in Ankleshwar, Gujarat, with a combined capacity exceeding 15,000 TPA. These facilities support a wide range of chemical reactions and are equipped with dedicated infrastructure and utilities.

Strategic Opportunities and Future Directions

Cohizon Life Sciences is committed to expanding its capabilities in the pharmaceutical sector, investing in new facilities and technologies to meet the growing demand for high-quality intermediates and APIs. The company aims to strengthen its position as a leading CDMO by focusing on innovation, sustainability, and customer-centric solutions.